logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Durvalumab in addition to chemotherapy for metastatic non-small-cell lung cancer – first line

< Back

Durvalumab in addition to chemotherapy for metastatic non-small-cell lung cancer – first line

Drugs

Cancer and Palliative Care

December 2019


Durvalumab in addition to chemotherapy is in clinical development for stage 4 nonsmall cell lung cancer (NSCLC). NSCLC makes up the majority of lung cancers in the UK. Stage 4 (advanced/metastatic) NSCLC is when the cancer has spread beyond the lung which was initially affected, most often to the liver, the adrenal glands, the bones and the brain. Most patients with NSCLC are diagnosed at the advanced/metastatic stage where curative treatment with surgery is unsuitable. Currently, chemotherapy remains the first line treatment option but this is often not well tolerated by many patients.
Durvalumab is given through intravenous infusion. It is a form of immunotherapy that works by increasing T-cell activity in order to stimulate the body’s immune system to fight cancerous cells. Durvalumab is already licensed in the UK for the treatment of a different form of NSCLC. Durvalumab may be more effective than chemotherapy alone which is the current standard of care and  may offer an additional treatment option for patients with NSCLC.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts